Fusion Antibodies Plc (GB:FAB) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Fusion Antibodies Plc has secured a contract to develop a therapeutic antibody to combat a chronic disease, expecting to generate £200,000 in revenue within the current financial year, along with future royalties from commercial sales. The company continues to leverage its expertise in antibody engineering, working closely with a long-standing US biotech client, with whom they have an ongoing $650,000 project. Fusion Antibodies’ growth strategy focuses on accelerating the drug development process for pharmaceutical and diagnostic companies.
For further insights into GB:FAB stock, check out TipRanks’ Stock Analysis page.
